NCT03434158 - Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 6, 2018

Primary Completion Date

May 12, 2022

Study Completion Date

May 12, 2022

Conditions

Prostate Cancer Metastatic

Interventions

DRUG

Olaparib

300 mg twice a day

Trial Locations (8)

Complejo Hospitalario Regional Reina Sofía, Córdoba

Complexo Hospitalario Universitario de Santiago, Santiago de Compostela

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario Central de Asturias, Oviedo

Fundación Instituto Valenciano de Oncología, Valencia

Hospital Universitario i Politècnic La Fe, Valencia

ICO L'Hospitalet, L'Hospitalet de Llobregat

Hospital Clínic de Barcelona, Barcelona